

Commentary

Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression

Amr Ahmed¹, Maher M. Akl²

1. The public health department, MSc degree in gynecology and obstetrics, Riyadh First Health Cluster, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia; 2. Mansoura University, Egypt

This manuscript explores various aspects related to the use of dual GLP-1 agonist with degludec basal insulin as a potential treatment approach for early type 1 diabetes. The background section highlights the destruction of beta cells in early type 1 diabetes and the emergence of GLP-1 agonists as a promising option for managing obesity and type 2 diabetes. The authors discuss a retrospective analysis of the efficacy of semaglutide, a GLP-1 agonist, in patients with newly diagnosed early type 1 diabetes. The results show the elimination of prandial and basal insulin, increased C-peptide levels, and improved glycemic control. However, the study's retrospective nature and lack of a control group emphasize the need for larger prospective trials. The interpretation section highlights the potential of GLP-1 agonists in protecting residual beta cells, stimulating cell proliferation, and reprogramming liver cells into insulin-producing cells. Moreover, modifying GLP-1 agonists with albumin ligands shows promise in extending their half-life and enhancing their anti-diabetic effects. The perspective section provides a comprehensive overview of the synergistic approach, considering the pharmacokinetic properties of degludec, the plasticity of adult human hepatic tissue, and the benefits of modified GLP-1 derivatives. The conclusion emphasizes the need for further research to explore the full potential of this approach in early type 1 diabetes treatment. The proposed approach offers a promising avenue for the treatment of early type 1 diabetes, integrating the autoimmune hypothesis, the proliferative effects of GLP-1, and modifications using albumin ligands. By combining these elements, we can strive towards restoring beta cell mass and function,

ultimately improving the lives of individuals living with type 1 diabetes. The manuscript is planned to undergo clinical trials in 2024, registered as 'Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists with Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus' with ClinicalTrials.gov Identifier NCT06057077.

Corresponding author: Maher M. Akl, maherakl555@gmail.com

1. Background

Type 1 diabetes is characterized by the destruction of beta cells, which necessitates the use of daily basal-bolus insulin as the primary treatment option. However, the emergence of drugs such as glucagon-like peptide 1 (GLP-1) agonists has brought new hope for the management of obesity and type 2 diabetes mellitus.^[1] Notably, the United States Food and Drug Administration (FDA) has approved the use of GLP-1 agonists for adolescents as young as 12 years old, making it a promising choice for various indications, including combating obesity at an early age.^[2] While the prolonged and stable effects of degludec (Deg), a basal insulin, are primarily attributed to its mechanism of action involving binding to albumin, it is crucial to consider the factors contributing to its stability and extended duration of effects.^[3]

In this manuscript, we aim to address a letter to the editor titled "**Semaglutide in Early Type 1 Diabetes**" by *Paresh Dandona, M.D., Ph.D., and Ajay Chaudhur, M.D., published in The New England Journal of Medicine on September 7, 2023*. The authors conducted a retrospective analysis to evaluate the efficacy of semaglutide, a GLP-1 agonist, in patients with newly diagnosed type 1 diabetes.

Their study included 10 patients aged between 21 and 39 who initiated semaglutide treatment within 3 months of their type 1 diabetes diagnosis. The patients were followed up for 12 months, and metabolic outcomes were analyzed. Some patients presented with diabetic ketoacidosis at the time of diagnosis, while others exhibited symptoms such as polyuria, polydipsia, and weight loss. Additionally, most patients had antibodies against glutamic acid decarboxylase. Semaglutide was administered initially at a weekly dose of 0.125 mg, and the dose of prandial insulin was gradually reduced while the semaglutide dose was increased. Within 3 months, prandial insulin was completely eliminated in all patients, and within 6 months, basal insulin was eliminated in 7 patients. Throughout the 12-month follow-up period, the mean glycated hemoglobin level decreased to 5.7–5.9%, the fasting C-peptide

level increased, and the time spent in the target glucose range improved. The authors compared their findings with control groups from four studies involving patients with early type 1 diabetes who were receiving insulin therapy. The results revealed that initiating semaglutide soon after the diagnosis of type 1 diabetes was associated with the elimination of prandial and basal insulin, increased C-peptide levels, and improved glycemic control. However, as this was a retrospective analysis and lacked a control group from their own study, the authors emphasized the need for prospective, randomized clinical trials with larger sample sizes to further investigate this approach. Despite its limitations, this small case series suggests the potential of semaglutide as a treatment option in early type 1 diabetes. The objective of this manuscript is to support and interpret this approach and propose an alternative approach that may be more effective.^[4]

2. Interpretation and Commentary on the Manuscript "Semaglutide in Early Type 1 Diabetes" by Paresh Dandona, M.D., Ph.D., and Ajay Chaudhur, M.D., published in The New England Journal of Medicine on September 7, 2023.

Comment 1: The presence of anti-GAD antibodies in most cases of type 1 diabetes suggests an autoimmune etiology. Early intervention with GLP-1 agonists may potentially protect residual beta cells and reverse the autoimmune response. It is suggested that GLP-1 agonists like semaglutide may discourage the release of these antibodies, leading to the reversal of beta cell dysfunction. The reversible binding of degludec to albumin allows for the release of insulin in the target tissue, resulting in glucose-lowering effects. Further investigations, such as measuring anti-GAD and anti-IA2 antibodies after stopping insulin, can provide valuable insights into the validity of this theory.^[5]

Comment 2: GLP-1 receptors are found in pancreatic islets, acini, and ducts. GLP-1 agonist therapy has been observed to stimulate proliferation in acinar and duct cells containing endocrine stem cells. Additionally, previous studies have suggested that pancreatic exocrine duct cells have the potential to differentiate into insulin-producing beta cells during embryogenesis but not after birth. The direct reprogramming of liver cells into insulin-producing cells offers another approach for cell replacement therapy.

The plasticity of adult human hepatic tissue and its ability to acquire pancreatic characteristics have been demonstrated in vitro. These findings highlight the potential of utilizing adult hepatic tissue for regenerative medicine approaches.^[6]

Comment 3: Modifying GLP-1 receptor agonists with albumin ligands specific for human serum albumin (HSA) has shown promise in extending the half-life of GLP-1 and enhancing its anti-diabetic effects. Rhein-C12-GLP-1, a derivative modified with Rhein, has demonstrated improved glucose tolerance and significant hypoglycemic effects in animal models. This modification could potentially increase the action time of GLP-1 and make it a viable option for the treatment of type 2 diabetes mellitus and as a long-acting anorectic agent. Further studies are needed to fully evaluate the potential of this modification, including molecular docking studies, pharmacokinetic assays, and pharmacology assays.^[7]

3. Perspective

The information provided suggests a comprehensive and interconnected perspective on the potential treatment of type 1 diabetes through the synergistic approach of dual GLP-1 agonist with degludec basal insulin. Type 1 diabetes is characterized by the destruction of beta cells, resulting in the need for daily basal-bolus insulin as the primary treatment option. However, the emergence of GLP-1 agonists offers new hope for the treatment of obesity and type 2 diabetes. These agonists have been approved by the FDA for adolescents as young as 12 years old, making them a promising choice for various indications, including combating obesity at an early age. The stability and prolonged effects of degludec basal insulin are attributed to its mechanism of action, which involves reversible binding to albumin. This allows for the release of more than 99% of the drug in the target tissue, exerting glucose-lowering effects. Notably, changes in albumin concentrations are unlikely to impact the pharmacokinetic properties of degludec due to the high levels of serum albumin. The bound insulin decreases at night, leading to increased free insulin levels and maintaining a constant association constant (K_a). This may result in a stronger effect of degludec at night, potentially causing nocturnal hypoglycemia.^[8]

Another intriguing approach discussed is the direct reprogramming of liver cells into insulin-producing cells, which could be a viable option for cell replacement therapy in diabetes. Experimental studies have shown that human liver cells possess significant cellular plasticity and can acquire

mesenchymal-like characteristics.^[9] Insulin-producing cells were primarily generated in cells enriched for adult hepatic markers that coexpress albumin and mesenchymal markers.

These findings suggest that adult human hepatic tissue retains a considerable level of developmental plasticity, which could be harnessed for regenerative medicine approaches.^[10] Furthermore, modifying GLP-1 receptor agonists with albumin ligands specific for human serum albumin (HSA) has proven to be an effective strategy for extending the half-life of GLP-1. This modification enhances the anti-diabetic profile of GLP-1, resulting in improved glucose tolerance and significant hypoglycemic effects.^[11] Rhein-C12-GLP-1, a derivative modified with Rhein, has shown promising hypoglycemic effects in animal models, surpassing the action time of the backbone peptide Arg34-GLP-1(7-37)-OH.^[12] It holds potential for the treatment of type 2 diabetes mellitus and could be developed as a long-acting anorectic agent. However, further evaluations, including molecular docking studies, pharmacokinetic assays, and pharmacology assays, are necessary to fully assess its potential. Evidence supports the autoimmune hypothesis as the basis for type 1 diabetes, characterized by the destruction of pancreatic beta cells and subsequent insulin deficiency.^[13] This hypothesis suggests that self-reactive T cells mistakenly target and attack beta cells, leading to their destruction. Autoantibodies against beta cell antigens, such as insulin, glutamic acid decarboxylase (GAD), and islet antigen-2 (IA-2), found in individuals with type 1 diabetes, serve as markers for the autoimmune process and provide insights into the disease's pathogenesis.^[14]

GLP-1, a peptide hormone secreted by intestinal L-cells, plays a critical role in glucose homeostasis.^[15] Apart from its insulintropic effects, GLP-1 has demonstrated the ability to promote cell proliferation and neogenesis in various tissues, including the pancreas.^{[16][17]} Studies have shown that activation of GLP-1 receptors stimulates the replication and survival of beta cells.^[18] This proliferative effect of GLP-1 on beta cells holds significant potential for the development of innovative therapeutic approaches in treating type1 diabetes, with the aim of restoring beta cell mass and function.^[19] To optimize the pharmacokinetic properties of GLP-1 and extend its duration of action, researchers have explored modifications using albumin ligands.^[20] Albumin, the most abundant protein in the blood plasma, has a long half-life and can reversibly bind to various drugs and hormones. By conjugating GLP-1 with specific albumin ligands, such as fatty acids or other chemical moieties, modified GLP-1 analogs exhibit enhanced binding affinity to albumin and prolonged circulation time.^[21] The use of albumin ligands in modification offers several advantages. Firstly, it

improves the stability and pharmacokinetic profile of the GLP-1 analog by reducing renal clearance and enzymatic degradation. ^{[22][23][24]} Secondly, the reversible binding of the modified GLP-1 analog to albumin facilitates its release at the target tissue, ensuring sustained therapeutic effects. ^[25] Additionally, the high levels of serum albumin act as a buffer against changes in albumin concentrations, minimizing potential variations in pharmacokinetics. ^[26]

4. Conclusion

The proposed theory of beta cell regeneration in type 1 diabetes through the synergistic approach of dual GLP-1 agonist with degludec basal insulin presents a comprehensive and interconnected perspective. This approach takes into account the unique pharmacokinetic properties of degludec, the potential plasticity of adult human hepatic tissue, and the promising outcomes of GLP-1 derivatives modified with albumin ligands. By combining these elements, there is potential for a transformative treatment strategy for type 1 diabetes. The autoimmune hypothesis, which supports the involvement of self-reactive T cells in the pathogenesis of type 1 diabetes, provides substantial evidence for the underlying mechanisms of the disease. Understanding the role of these cells in the destruction of beta cells is crucial for developing effective interventions. Moreover, the proliferative effects of GLP-1 on beta cell replication offer promise for novel therapeutic interventions in type 1 diabetes. By stimulating beta cell replication and enhancing their survival, GLP-1 holds the potential to restore beta cell mass and function, which is essential for glucose homeostasis. Additionally, modifications using albumin ligands offer a strategy to optimize the pharmacokinetic properties of GLP-1.

By conjugating GLP-1 with albumin-specific ligands, the resulting modified GLP-1 analogs exhibit enhanced binding affinity to albumin, prolonging their circulation time and improving stability. This approach has the potential to provide sustained therapeutic effects and minimize potential pharmacokinetic variations. Despite these advancements, further research and clinical investigations are necessary to fully explore the potential of these approaches in managing type 1 diabetes. Continued efforts in understanding the autoimmune basis of the disease, refining GLP-1 analogs, and evaluating their efficacy in clinical settings will be crucial in advancing the field. The present hypothesis has been registered for undergoing clinical trials in 2024 under the title 'Amr Ahmed, Maher M. Akl, Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus.' Additionally, the ClinicalTrials.gov Identifier for this study is **NCT06057077**.

Statements and Declarations

The authors declare that there are no conflicts of interest.

References

1. [△]Akil AA, Yassin E, Al-Maraghi A, Aliyev E, Al-Malki K, Fakhro KA. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. *J Transl Med.* 2021 Apr 1;19(1):137. doi: 10.1186/s12967-021-02778-6. PMID: 33794915; PMCID: PMC8017850.
2. [△]Yan Y, Gong Y, Jiang M, Gao Y, Guo S, Huo J, Zhao Z, Li C. Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study. *Front Endocrinol (Lausanne).* 2023 Jun 13;14:1170127. doi: 10.3389/fendo.2023.1170127. PMID: 37383395; PMCID: PMC10293789.
3. [△]Kawaguchi Y, Sawa J, Sakuma N, Kumeda Y. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles. *J Diabetes Investig.* 2019 Mar;10(2):343–351. doi: 10.1111/jdi.12884. Epub 2018 Jul 28. PMID: 29947060; PMCID: PMC6400202.
4. [△]Semaglutide in Early Type 1 Diabetes Paresh Dandona, *The New England Journal of Medicine* on September 7, 2023 *N Engl J Med* 2023; 389:958–959 DOI: 10.1056/NEJMc2302677.
5. [△]Wang W, Huang F, Han C. Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-analysis. *Diabetes Ther.* 2023 Oct;14(10):1723–1752. doi: 10.1007/s13300-023-01459-5. Epub 2023 Aug 16. PMID: 37584857; PMCID: PMC10499777.
6. [△]Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. *Pharmacol Ther.* 2007 Mar;113(3):546–93. doi: 10.1016/j.pharmthera.2006.11.007. Epub 2006 Dec 28. PMID: 17306374; PMCID: PMC1934514.
7. [△]Tan H, Su W, Zhang W, Zhang J, Sattler M, Zou P. Albumin-binding domain extends half-life of glucagon-like peptide-1. *Eur J Pharmacol.* 2021 Jan 5;890:173650. doi: 10.1016/j.ejphar.2020.173650. Epub 2020 Oct 10. PMID: 33049303.
8. [△]Knudsen LB and Lau J (2019) The Discovery and Development of Liraglutide and Semaglutide. *Front. Endocrinol.* 10:155. doi: 10.3389/fendo.2019.00155.
9. [△]Meivar-Levy I, Ferber S. Reprogramming of liver cells into insulin-producing cells. *Best Pract Res Clin Endocrinol Metab.* 2015 Dec;29(6):873–82. doi: 10.1016/j.beem.2015.10.006. Epub 2015 Oct 8. PMID: 26696516.

10. [△]Meivar-Levy I, Sapir T, Berneman D, Weissbach T, Polak-Charcon S, Ravassard P, Tzakis AG, Mor E, Ricordi C, Ferber S. Human liver cells expressing albumin and mesenchymal characteristics give rise to insulin-producing cells. *J Transplant*. 2011;2011:252387. doi: 10.1155/2011/252387. Epub 2011 Aug 24. PMID: 21876779; PMCID: PMC3163017.
11. [△]Sun X, Zhang Z, Liu M, Zhang P, Nie L, Liu Y, Chen Y, Xu F, Liu Z, Zeng Y. Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives. *Biomed Pharmacother*. 2022 Apr;148:112722. doi: 10.1016/j.biopha.2022.112722. Epub 2022 Feb 21. PMID: 35202915.
12. [△]Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. *Biochim Biophys Acta Mol Basis Dis*. 2023 Oct;1869(7):166770. doi: 10.1016/j.bbadis.2023.166770. Epub 2023 Jun 3. PMID: 37276988.
13. [△]Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β -cell (do not blame the immune system?). *Nat Rev Endocrinol*. 2021 Mar;17(3):150-161. doi: 10.1038/s41574-020-00443-4. Epub 2020 Dec 8. PMID: 33293704; PMCID: PMC7722981.
14. [△]Burrack AL, Martinov T, Fife BT. T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes. *Front Endocrinol (Lausanne)*. 2017 Dec 5;8:343. doi: 10.3389/fendo.2017.00343. PMID: 29259578; PMCID: PMC5723426.
15. [△]Nadkarni P, Chepurny OG, Holz GG. Regulation of glucose homeostasis by GLP-1. *Prog Mol Biol Transl Sci*. 2014;121:23-65. doi: 10.1016/B978-0-12-800101-1.00002-8. PMID: 24373234; PMCID: PMC4159612.
16. [△]Kaneto H, Kimura T, Shimoda M, Obata A, Sanada J, Fushimi Y, Nakanishi S, Mune T, Kaku K. Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β -Cell Glucose Toxicity and the Development of Arteriosclerosis: "The Earlier, the Better" in Therapy with Incretin-Based Medicine. *Int J Mol Sci*. 2021 Jul 24;22(15):7917. doi: 10.3390/ijms22157917. PMID: 34360682; PMCID: PMC8348147.
17. [△]Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. *Pharmacol Ther*. 2007 Mar;113(3):546-93. doi: 10.1016/j.pharmthera.2006.11.007. Epub 2006 Dec 28. PMID: 17306374; PMCID: PMC1934514.
18. [△]Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. *Exp Diabetes Res*. 2011;2011:376509. doi: 10.1155/2011/376509. Epub 2011 May 22. PMID: 21716694; PMCID: PMC3118608.

19. [△]Eguchi N, Toribio AJ, Alexander M, Xu I, Whaley DL, Hernandez LF, Dafoe D, Ichii H. Dysregulation of β -Cell Proliferation in Diabetes: Possibilities of Combination Therapy in the Development of a Comprehensive Treatment. *Biomedicines*. 2022 Feb 17;10(2):472. doi: 10.3390/biomedicines10020472. PMID: 35203680; PMCID: PMC8962301.
20. [△]Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. *Front Endocrinol (Lausanne)*. 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. PMID: 31031702; PMCID: PMC6474072.
21. [△]Bech EM, Pedersen SL, Jensen KJ. Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. *ACS Med Chem Lett*. 2018 Jun 15;9(7):577–580. doi: 10.1021/acsmchemlett.8b00226. PMID: 30034579; PMCID: PMC6047018.
22. [△]Han, J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H. and Huang, W. (2014), Discovery of coumarin modified GLP-1 derivatives. *Br J Pharmacol*, 171: 5252–5264. <https://doi.org/10.1111/bph.12843>.
23. [△]Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. *Front Endocrinol (Lausanne)*. 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. PMID: 31031702; PMCID: PMC6474072.
24. [△]Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Müller TD, Haqq AM. Recent Advances in Incrétin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes. *Front Endocrinol (Lausanne)*. 2022 Mar 1;13:838410. doi: 10.3389/fendo.2022.838410. PMID: 35299971; PMCID: PMC8921987.
25. [△]Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). *Mol Metab*. 2019 Dec;30:72–130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. PMID: 31767182; PMCID: PMC6812410.
26. [△]Yu YT, Liu J, Hu B, Wang RL, Yang XH, Shang XL, Wang G, Wang CS, Li BL, Gong Y, Zhang S, Li X, Wang L, Shao M, Meng M, Zhu F, Shang Y, Xu QH, Wu ZX, Chen DC. Expert consensus on the use of human serum albumin in critically ill patients. *Chin Med J (Engl)*. 2021 Jul 20;134(14):1639–1654. doi: 10.1097/CM9.0000000000001661. PMID: 34397592; PMCID: PMC8318641.

Declarations

Funding: No specific funding was received for this work.

Potential competing interests: No potential competing interests to declare.